Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer

BACKGROUND: Although SARS-CoV-2 vaccines immunogenicity in patients with cancer has been investigated, whether they can significantly improve the severity of COVID-19 in this specific population is undefined. METHODS: Capitalizing on OnCovid (NCT04393974) registry data we reported COVID-19 mortality...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinato, David J., Ferrante, Daniela, Aguilar-Company, Juan, Bower, Mark, Salazar, Ramon, Mirallas, Oriol, Sureda, Anna, Bertuzzi, Alexia, Brunet, Joan, Lambertini, Matteo, Maluquer, Clara, Pedrazzoli, Paolo, Biello, Federica, Lee, Alvin J.X., Sng, Christopher C.T., Liñan, Raquel, Rossi, Sabrina, Carmona-García, M.Carmen, Sharkey, Rachel, Eremiev, Simeon, Rizzo, Gianpiero, Bain, Hamish DC., Yu, Tamara, Cruz, Claudia A., Perachino, Marta, Saoudi-Gonzalez, Nadia, Fort-Culillas, Roser, Doonga, Kris, Fox, Laura, Roldán, Elisa, Zoratto, Federica, Gaidano, Gianluca, Ruiz-Camps, Isabel, Bruna, Riccardo, Patriarca, Andrea, Shawe-Taylor, Marianne, Fusco, Vittorio, Martinez-Vila, Clara, Berardi, Rossana, Filetti, Marco, Mazzoni, Francesca, Santoro, Armando, Delfanti, Sara, Parisi, Alessandro, Queirolo, Paola, Aujayeb, Avinash, Rimassa, Lorenza, Prat, Aleix, Tabernero, Josep, Gennari, Alessandra, Cortellini, Alessio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124924/
https://www.ncbi.nlm.nih.gov/pubmed/35704976
http://dx.doi.org/10.1016/j.ejca.2022.04.036
Descripción
Sumario:BACKGROUND: Although SARS-CoV-2 vaccines immunogenicity in patients with cancer has been investigated, whether they can significantly improve the severity of COVID-19 in this specific population is undefined. METHODS: Capitalizing on OnCovid (NCT04393974) registry data we reported COVID-19 mortality and proxies of COVID-19 morbidity, including post-COVID-19 outcomes, according to the vaccination status of the included patients. RESULTS: 2090 eligible patients diagnosed with COVID-19 between 02/2020 and 11/2021 were included, of whom 1930 (92.3%) unvaccinated, 91 (4.4%) fully vaccinated and 69 (3.3%) partially vaccinated. With the exception of a higher prevalence of patients from the UK (p = 0.0003) and receiving systemic anticancer therapy at COVID-19 diagnosis (p = 0.0082) among fully vaccinated patients, no demographics/oncological features were associated with vaccination status. The 14-days case fatality rate (CFR) (5.5% vs 20.7%, p = 0.0004) and the 28-days CFR (13.2% vs 27.4%, p = 0.0028) demonstrated a significant improvement for fully vaccinated patients in comparison with unvaccinated patients. The receipt of prior full vaccination was also associated with reduced symptomatic COVID-19 (79.1% vs 88.5%, p = 0.0070), need of COVID-19 oriented therapy (34.9% vs 63.2%, p < 0.0001), complications from COVID-19 (28.6% vs 39.4%, p = 0.0379), hospitalizations due to COVID-19 (42.2% vs 52.5%, p = 0.0007) and oxygen therapy requirement (35.7% vs 52%, p = 0.0036). Following Inverse Probability Treatment Weighting (IPTW) procedure no statistically significant difference according to the vaccination status was confirmed; however, all COVID-19 related outcomes were concordantly in favour of full vaccination. Among the 1228 (58.8%) patients who underwent a formal reassessment at participating centres after COVID-19 resolution, fully vaccinated patients experienced less sequelae than unvaccinated patients (6.7% vs 17.2%, p = 0.0320). CONCLUSIONS: This analysis provides initial evidence in support of the beneficial effect of SARS-CoV-2 vaccines against morbidity and mortality from COVID-19 in patients with cancer.

Ejemplares similares